证券代码：600055 证券简称：万东医疗 编号：临 2025-042 北京万东医疗科技股份有限公司 关于公司及子公司使用闲置募集资金 及自有资金进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法 律责任。 重要内容提示： 产品种类：银行理财 本次现金管理总额：自有资金 0.8 亿元 履行的审议程序：2025年 3月 20日召开的第十届董事会第六次会议、 第十届监事会第六次会议及 2025 年 4 月 16 日召开的 2024 年年度股东大会 审议批准《关于使用部分暂时闲置募集资金及自有资金进行现金管理的议 案》。 一、情况概述 （一）现金管理目的 北京万东医疗科技股份有限公司（以下简称"公司"）及子公司为提 高募集资金和自有资金效率，合理利用部分闲置募集资金及自有资金，在 确保不影响募集资金项目建设和使用、募集资金和自有资金安全的情况下， 增加公司的收益，为公司及股东获取更多回报。 （二）现金管理金额 本次现金管理总金额为：公司使用自有资金 0.1 亿元， 子公司使用自 有资金 0.7 亿元。 （三）资金来源 ...

特此公告。 北京万东医疗科技股份有限公司（以下简称"公司"）于 2025 年 8 月 22 日召开第十届董事会第十次会议，审议通过了《关于以集中竞价交易方 式回购公司股份方案的议案》。具体内容详见公司于 2025 年 8 月 23 日在上 海证券交易所网站披露的《万东医疗关于以集中竞价交易方式回购股份方 案的公告》（公告编号：2025-038）。 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指 引第7号—回购股份》等相关规定，现将董事会公告回购股份决议的前一个 交易日（即2025年8月22日）登记在册的前十大股东和前十大无限售条件股 东的名称、持股数量及比例情况公告如下： | 序号 | 股东名称 | 持股数量（股） | 占总股本比例 | | --- | --- | --- | --- | | | | | （%） | | 1 | 美的集团股份有限公司 | 319,579,981 | 45.46 | | 2 | 江苏鱼跃科技发展有限公司 | 18,031,825 | 2.56 | | 3 | 中国银行股份有限公司－华宝中证医疗 交易型开放式指数证券投资基金 | 12,687,111 | 1.80 ...

Core Insights - The article discusses the emerging opportunities in the intraoperative MRI (iMRI) market, particularly highlighting the advancements made by domestic companies like Zhongjia Health and Yiying Medical in the context of increasing competition and market demand [1][10]. Market Overview - The global market for intraoperative MRI devices is projected to reach $1.22 billion by 2025, with a compound annual growth rate (CAGR) of 8.5%, and expected to grow to $2.77 billion by 2035 [1]. - The Asia-Pacific region, including China, is anticipated to grow at the fastest rate of 8.6% CAGR, driven by price advantages from centralized procurement, increased penetration of minimally invasive surgeries, and rapid advancements in AI technology [1]. Technological Advancements - iMRI integrates MRI imaging technology with surgical procedures, providing real-time, high-resolution images of the surgical area, which enhances surgical precision and decision-making [2]. - iMRI has shown significant clinical advantages in neurosurgery, improving the complete resection rate of brain tumors from 54.39% to 83.34% [3]. Competitive Landscape - Companies like Cook Medical and Siemens Healthineers are actively investing in iMRI technology, with Cook Medical establishing a dedicated division for interventional MRI with an initial investment of $230 million [3][4]. - Siemens has already formed partnerships to commercialize MRI-guided treatments, indicating a mature strategy in the iMRI space [4]. Challenges in Adoption - The high cost of iMRI systems and the complexity of required infrastructure hinder widespread adoption in domestic hospitals, with only 350 units installed in China as of 2023 [6]. - The construction of an iMRI-compatible surgical environment can cost between 30 million to 90 million yuan, depending on the specifications [6]. Future Prospects - The integration of AI technologies, such as GE's Sonic DL algorithm, is expected to enhance the functionality of iMRI, potentially expanding its application in various clinical scenarios [8]. - Companies need to establish a comprehensive supply chain and identify optimal clinical applications to maximize the value of iMRI technology [10].

Core Insights - Community home-based elderly care services are a crucial supplement to traditional family care models, addressing the needs of the aging population in China and alleviating the burden on family caregivers [1][10] - The market size of China's community home-based elderly care services is projected to grow from 52.42 billion yuan in 2016 to 1,149.12 billion yuan by 2024, with a compound annual growth rate (CAGR) of 47.1% [1][10] - By 2025, the market size is expected to reach 1,310.4 billion yuan, driven by the deepening aging process and the continuous improvement of the elderly care service system [1][10] Industry Overview - Community home-based elderly care services integrate family, community, and social resources to provide specialized support for elderly individuals living at home, including daily care and rehabilitation services [3][5] - The service model includes home visits and daytime care, covering 14 basic service categories such as meal assistance, bathing assistance, and health monitoring [3][5] Market Dynamics - The number of individuals aged 65 and above in China has increased from 144.24 million in 2015 to an estimated 220.23 million by 2024, with an aging rate rising from 10.5% to 15.64% during the same period [8] - The growing elderly population and the resulting demand for daily care services are driving the development of community-based home care models, which are part of the "9073" elderly care system [8] Policy Support - The Chinese government has introduced various policies to support the community home-based elderly care sector, including financial subsidies, tax incentives, and standard regulations, which have stimulated market vitality and diversified service supply [8][10] - Recent policies aim to enhance the basic elderly care service system, promote community-based care, and encourage the integration of community resources for elderly services [8][10] Industry Structure - The community home-based elderly care service industry features a diverse competitive landscape, including government-supported public organizations, market-oriented professional institutions, and community social organizations [11] - Key players in the industry include Beijing Sijiejiatong Information Technology Co., Ltd., Lion City Yian (Shanghai) Property Management Co., Ltd., and Jiangsu Ruizhikang Health Industry Group Co., Ltd., among others [11][12] Future Trends - The integration of smart technology and data analytics is expected to enhance service efficiency in community home-based elderly care, with applications such as health monitoring devices and AI-assisted care [12][13] - There will be a growing emphasis on personalized and customized services tailored to the specific needs of elderly individuals, including health management and psychological support [13] - Increased government support is anticipated, including expanded long-term care insurance trials and improved regulatory frameworks to enhance service quality and protect elderly rights [14][15]

Core Insights - The company reported a revenue of 843 million yuan, representing a year-on-year increase of 20.46% [1] - The net profit attributable to shareholders was 51.3 million yuan, showing a year-on-year decline of 39.46% [1] - Research and development investment increased by 59.16%, with an R&D intensity of 15% [1] Business Strategy - The company is leveraging the "Healthy China 2030" strategy, focusing on breakthroughs in high-end medical imaging equipment technology and global market expansion [1] - In response to global supply chain adjustments and structural upgrades in the industry, the company is enhancing its R&D system, deepening market layout, and optimizing industrial collaboration [1] Technological Advancements - The company has made significant technological progress, with one-third of its workforce dedicated to R&D, focusing on high-end CT and self-developed core components [1] - The world's first helium-free MR has achieved mass production, eliminating the "bottleneck" risk associated with helium supply [1] - The quantum DSA, utilizing a self-controlled rare earth detector, is leading the way in low-dose angiography [1] - As of June 2025, the company has been granted 243 authorized intellectual property rights, which are widely applied in its main business [1]

Policy Developments - The National Healthcare Security Administration held a training session on accelerating the construction of a long-term care insurance system, emphasizing the need for a unified and independent insurance model, multi-channel funding, and digital management to enhance service efficiency [2] Drug and Medical Device Approvals - Kangyuan Pharmaceutical received clinical trial approval for its Jin Zhen oral liquid to treat children's influenza, indicating a promising market outlook for this pediatric traditional Chinese medicine [4] - AstraZeneca's Datroway® was approved for use in treating hormone receptor-positive, HER2-negative breast cancer in adults who have previously undergone endocrine therapy and at least one line of chemotherapy, based on positive results from a global Phase III study [5] - Xianju Pharmaceutical's dexamethasone acetate tablets passed the consistency evaluation for generic drugs, which will enhance the company's market competitiveness [6] Financial Reports - Pian Zai Huang reported a 4.81% decline in total revenue to 5.379 billion yuan and a 16.22% decrease in net profit to 1.442 billion yuan for the first half of 2025, while advancing multiple new drug projects [8] - Wandong Medical achieved a 20.46% increase in revenue to 843 million yuan, but net profit fell by 39.46% to 51.3 million yuan, despite a 59.16% rise in R&D investment [9] - Huangshan Capsule reported a 3.66% increase in revenue to 244 million yuan and a 19.78% rise in net profit to 35.6 million yuan for the first half of 2025 [10] Capital Markets - Kexing Pharmaceutical announced plans to list on the Hong Kong Stock Exchange to enhance its international competitiveness and optimize its capital structure [12] - Tongce Medical acquired a 100% stake in Shanghai Congji Dental Clinic for 46 million yuan, aiming to enhance brand presence in the high-end market [13] Industry Developments - China's pharmaceutical industry ranks second globally, with approximately 30% of the world's innovative drugs under development, reflecting significant growth driven by policy, technology, and capital influx [15]

Core Points - WanDong Medical's stock price increased by 2.67% to 18.05 yuan as of August 22, 2025, with a market capitalization of 12.69 billion yuan [1] - The company reported a decrease in the number of shareholders by 11.69% to 26,800 as of June 30, 2025, with an increase in average shareholding [2][5] - The company's mid-year report for 2025 showed a 20.46% increase in revenue to 843.33 million yuan, but a significant decline in net profit by 39.46% to 51.30 million yuan [3][5] Shareholder Changes - As of June 30, 2025, the number of shareholders decreased by 3,552, representing an 11.69% reduction [2][5] - The average number of shares held per shareholder increased from 23,100 to 26,200, with an average holding value of 452,800 yuan [2] Performance Highlights - For the first half of 2025, the company reported a total revenue of 843.33 million yuan, a year-on-year increase of 20.46% [3] - The net profit attributable to shareholders decreased by 39.46% to 51.30 million yuan, while the net profit excluding non-recurring items fell by 56.07% to 35.63 million yuan [3] - The second quarter of 2025 saw a revenue of 470 million yuan, up 20.04% year-on-year, but net profit dropped by 68.44% to 16.25 million yuan [3] Corporate Announcements - The board approved the 2025 semi-annual report and a stock option incentive plan, granting 1.2 million stock options to 14 individuals at an exercise price of 15.05 yuan per share [4][6] - The company plans to repurchase shares worth between 30 million and 60 million yuan, with a maximum repurchase price of 25 yuan per share [6]

Core Viewpoint - The company plans to repurchase shares through a centralized bidding process, with a total amount ranging from RMB 30 million to 60 million, aimed at employee stock ownership plans or equity incentives [1][2][4]. Summary by Sections Repurchase Plan Overview - The repurchase amount is set between RMB 30 million and 60 million [1][2]. - The funding source for the repurchase will be the company's own funds [1][5]. - The maximum repurchase price is capped at RMB 25 per share, which is 150% of the average trading price over the last 30 trading days prior to the board's decision [1][4]. - The repurchase will be conducted via centralized bidding [1][3]. - The duration for the repurchase is 12 months from the board's approval [1][3]. Purpose and Use of Repurchased Shares - The repurchased shares will be used for employee stock ownership plans or equity incentives [1][3][4]. - If the shares are not fully utilized for these purposes within three years, the company will follow the necessary procedures to cancel the unused shares and reduce registered capital accordingly [4][5]. Implementation and Conditions - The repurchase plan requires approval from at least two-thirds of the board members and does not need to be submitted to the shareholders' meeting [2][3]. - The estimated number of shares to be repurchased is between 120,000 and 240,000, representing 0.17% to 0.34% of the total share capital [2][4]. - The company will adjust the repurchase price if there are any capital changes, such as stock splits or dividends [4][5]. Financial Impact - The total amount for the repurchase represents approximately 1.10% of the company's total assets and 1.26% of the equity attributable to the parent company [5]. - The company asserts that the repurchase will not significantly impact its daily operations, financial status, research and development, profitability, or debt servicing capabilities [5][6]. Management and Compliance - The board has authorized the management to handle all matters related to the repurchase, including adjustments based on market conditions [7]. - There are no current plans for share reduction by directors, senior management, or major shareholders in the next three to six months [6][8].

Group 1 - The latest stock price of Wandong Medical is 18.05 yuan, up 0.84% from the previous trading day, with an opening price of 17.89 yuan, a high of 18.14 yuan, and a low of 17.86 yuan, with a trading volume of 98,145 hands and a transaction amount of 177 million yuan [1] - Wandong Medical focuses on the research, production, and sales of medical imaging equipment, including CT, MRI, and DR devices, and has made significant technological advancements, including the clinical validation of the world's first helium-free superconducting MRI and the application of multiple AI technologies [1] - The latest semi-annual report for 2025 shows that the company achieved an operating income of 843 million yuan in the first half of the year, a year-on-year increase of 20.46%, but the net profit attributable to shareholders decreased by 39.46% to 51.3 million yuan [1] - In the second quarter, the operating income was 470 million yuan, a year-on-year increase of 20.0%, while the net profit attributable to shareholders dropped by 68.4% to 16.25 million yuan [1] - The company's R&D investment increased by 59.16% year-on-year, with an R&D intensity of 15% [1] Group 2 - The net inflow of main funds for Wandong Medical today was 11.07 million yuan, with a cumulative net inflow of 8.30 million yuan over the past five days [2]

Core Viewpoint - The report discusses the stock option incentive plan of Beijing Wandong Medical Technology Co., Ltd. for 2025, detailing the approval process and compliance with relevant regulations [1][2][3]. Summary by Sections 1. Definition and Terms - The report defines key terms related to the stock option incentive plan, including "incentive objects," "grant date," "exercise price," and "exercise conditions" [1]. 2. Approval Process - The company held multiple meetings to approve the stock option incentive plan, including the sixth meeting of the tenth board of directors on March 20, 2025, and the sixth meeting of the tenth supervisory board on the same day [4][5]. - The plan was publicly disclosed from March 28 to April 8, 2025, with no objections raised by employees [4]. - The annual shareholders' meeting on April 16, 2025, approved the plan and authorized the board to handle related matters [4]. 3. Compliance and Conditions - The independent financial advisor confirmed that the incentive plan met all necessary conditions and approvals as per the regulations [6][8]. - The report outlines that the company and the incentive objects have not encountered any disqualifying circumstances as per the management regulations [7]. 4. Granting Details - A total of 120 stock options were granted to 14 core personnel, representing 11.11% of the total options planned for issuance [8]. - The total number of stock options involved in the incentive plan does not exceed 1% of the company's total equity [8]. 5. Financial Impact - The independent financial advisor recommends that the company account for the expenses related to the stock option plan in accordance with relevant accounting standards, noting potential dilution effects [8]. 6. Conclusion - The independent financial advisor concludes that the stock option incentive plan has obtained the necessary approvals and complies with all relevant laws and regulations, ensuring no harm to the company or its shareholders [9].